Platelet Concentration Thresholds in PRP—The Need for Standardized Quantification and Dose-Response Modeling: Letter to the Editor

Abstract

Get full access to this article

View all access options for this article.

References

Bensa

Previtali

Sangiorgio

, et al. PRP injections for the treatment of knee osteoarthritis: the improvement is clinically significant and influenced by platelet concentration. Am J Sports Med. 2025;53(3):745-754.

Dohan Ehrenfest

Rasmusson

Albrektsson

Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol. 2009;27(3):158-167.

Gajewski

Hart

Bergquist-Ulloa

, et al. Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials. Stat Med. 2019;38(17):3123-3138.

Giusti

D’Ascenzo

Mancò

, et al. Platelet concentration in platelet-rich plasma affects tenocyte behavior in vitro. Biomed Res Int. 2014;2014:630870.

Harrison

The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1895-1900.

Macdougall

. Analysis of dose-response studies: Emax model. In: Ting

, ed. Dose Finding in Drug Development. Springer; 2006:127-145.

Murray

Geeslin

Goudie

, et al. Minimum Information for Studies Evaluating Biologics in Orthopaedics (MIBO): platelet-rich plasma and mesenchymal stem cells. J Bone Joint Surg Am. 2017;99(10):809-819.

Saltzman

Leroux

Meyer

, et al. A greater platelet dose may yield better clinical outcomes for platelet-rich plasma in the treatment of knee osteoarthritis: a systematic review. Arthroscopy. 2025;41(3):809-817.e2.